SuperworthBiocryst Pharmaceuticals profit margin BCRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.
- Net margin, 12 months
- −40.9%
- Operating margin, 12 months
- −33.3%
- Net margin on a year earlier
- −34.5 pts
- Peer median
- 22.2%
Over the twelve months to Jun 30, 2026, Biocryst Pharmaceuticals kept −40.9% of its revenue as net profit, with an operating margin of −33.3% and a gross margin of 97.8%.
The median for 10 biotech stocks of a similar size is 22.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 30.2% | 39.0% | 97.8% |
| FY2024 | −19.7% | −0.6% | 97.3% |
| FY2023 | −68.4% | −31.3% | 98.6% |
| FY2022 | −91.2% | −54.8% | 97.6% |
| FY2021 | n/a | n/a | 95.4% |
| FY2020 | n/a | n/a | 91.3% |
| FY2019 | n/a | n/a | 92.4% |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | −89.1% | −81.7% | 97.2% |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −40.9% | −34.5 pts | −33.3% | |
| Q1 FY26 | −51.7% | −41.1 pts | −43.1% | |
| Q4 FY25 | 30.2% | +49.9 pts | 39.0% | |
| Q3 FY25 | −1.5% | +28.5 pts | 12.7% | |
| Q2 FY25 | −6.4% | +31.8 pts | 9.7% | |
| Q1 FY25 | −10.6% | +48.1 pts | 6.6% | |
| Q4 FY24 | −19.7% | +48.6 pts | −0.6% | |
| Q3 FY24 | −30.0% | +44.4 pts | −9.9% | |
| Q2 FY24 | −38.2% | +41.0 pts | −15.8% | |
| Q1 FY24 | −58.7% | +19.4 pts | −25.3% | |
| Q4 FY23 | −68.4% | +22.9 pts | −31.3% | |
| Q3 FY23 | −74.4% | +6.7 pts | −33.8% |
Against its peers
Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| BCRXBiocryst Pharmaceuticals | −40.9% |
| VCELVericel | 7.9% |
| ADMAAdma Biologics | 33.0% |
| MGTXMeiraGTx | 19.9% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| PLXProtalix BioTherapeutics | 23.5% |
| Peer median | 22.2% |
Where Biocryst Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Biocryst Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.